In our study, we found that elevated baseline serum S100B levels were associated with a higher risk of progression and death compared with normal baseline serum S100B levels in BRAF V600 mutant metastatic melanoma patients treated with BRAF + MEK inhibitors. Here, BRAF is linked to metastatic melanoma.